what is the difference
NAD+ and peptides
NAD+ is a coenzyme built from two nucleotides, filed on peptide menus for reasons of commerce rather than chemistry, and the difference changes what its evidence base contains.
NAD+ is nicotinamide adenine dinucleotide, a coenzyme every living cell uses to carry electrons through metabolism. Its name describes its structure exactly: two nucleotides, one carrying nicotinamide and one carrying adenine, joined back to back through their phosphate groups. A peptide is a different kind of object altogether. It is a chain of amino acids linked by peptide bonds, and the word names the chain rather than any particular job the chain does.
Those two definitions do not meet anywhere. There is no amino acid in NAD+ and no peptide bond in it, so no definition of the word peptide reaches the molecule. It nonetheless sits in the peptide aisle of almost every storefront and clinic that sells one, and it is the most frequently miscategorised substance in this whole catalog. This page sets out what each thing is, where the regulatory boundaries between them fall, and what the published record covers for the oral and the injected forms, which turn out to be two different literatures.
Not medical advice
This page reports what has been documented about a compound. It is not medical advice, not a diagnosis, not a dosing protocol, and not a recommendation to obtain or use anything described here. Talk to a licensed clinician about anything concerning your health. Read the full disclaimer.
Reviewed against editorial standards Updated
The short answer
NAD+ is a dinucleotide coenzyme, not a peptide, and it is not a chain of amino acids at any length. The reason it appears beside peptides is that the same clinics and storefronts carry both, and the word peptide has drifted into service as a category name for anything injected under a wellness heading.
The distinction changes which evidence belongs to what. The trial literature quoted for NAD+ is mostly about two oral precursors, nicotinamide mononucleotide and nicotinamide riboside, both sold as dietary supplements. The injected form is a different object, and a 2026 systematic review that went looking for outcomes trials of it reported finding none that met its criteria [1].
Side by side
| Property | NAD+ | Peptides as a class |
|---|---|---|
| What the molecule is | Nicotinamide adenine dinucleotide: two nucleotides, one carrying nicotinamide and one carrying adenine, joined through their phosphate groups | A chain of amino acids joined by peptide bonds, from two residues upward. The word names the chain, not a function |
| Amino acids in the structure | None, and no peptide bond anywhere in it | Every residue in the molecule, which is what the word means |
| Where the regulatory size line falls | Off that scale entirely, because it is neither a peptide nor a protein | FDA's final rule of 21 February 2020 defines a protein as any alpha amino acid polymer with a specific, defined sequence greater than 40 amino acids in size. At or below 40 residues a synthetic chain is handled as a drug, and above that line it is generally a biological product [4] |
| Forms people encounter | Two oral precursors sold as dietary supplements, nicotinamide mononucleotide and nicotinamide riboside, and separately an injected or infused form | Varies by compound, and this site covers each one separately with the route named on every result |
| Registered human record | On 2 August 2026 the registry returned 49 studies for nicotinamide mononucleotide and 124 for nicotinamide riboside. A free-text search on NAD+ and intravenous returned 44, and opening all 44 leaves five that name an NAD+ or precursor intervention; the rest match on the word intravenous alone [6] | Counted per compound on each group page, and the counting rule is that a registration is not a trial and a search hit is not a registration |
| Published outcomes trials of the injected form | A 2026 PRISMA-guided systematic review searched for outcomes trials of intravenous or intramuscular NAD+ for anti-ageing or wellness indications and reported that none met its inclusion criteria [1] | Compound by compound, and this site grades each on what tested that compound rather than a relative |
| US approval status | A query of FDA's approved-products data on 2 August 2026 returned no application for nicotinamide adenine dinucleotide, nicotinamide mononucleotide or nicotinamide riboside [5] | Most compounds in this catalog hold no US approval. A small number do, under an indication narrower than the one they are marketed for |
| Anti-doping position | The 2026 WADA Prohibited List caps intravenous infusions at 100 mL per 12 hour period under M2.2, so a large-volume drip is a prohibited method for a tested athlete whatever is in the bag [7] | Reached as substances, under classes S0, S2 and others, rather than by a rule about volume |
Why the two get mixed up
The shelf came first and the chemistry was never consulted. Clinics offering injected wellness products tend to offer all of them, storefronts organise their catalogs by who buys rather than by what a molecule is, and a category page needs a heading. Peptide became that heading, and it now covers a set of substances whose only shared property is being sold in a vial to people interested in performance, recovery or ageing.
The word itself is easy to stretch, because it names a structure rather than an effect. Insulin is a peptide. So is a two amino acid sweetener. FDA's own boundary is a length: its 2020 final rule fixes the line between a protein and everything shorter at 40 amino acids, with a defined sequence required on either side of it [4]. NAD+ has no sequence to measure, because it is not built from amino acids at all.
NAD+ is also not the only substance on that shelf that is not a peptide, which is worth stating because the same mislabelling moves evidence between molecules. 5-Amino-1MQ is a small ring molecule that inhibits an enzyme in nicotinamide handling. MK-677 is an orally active small molecule, studied in a two year randomised trial in healthy older adults [8]. Follistatin-344 is a 344 amino acid glycoprotein, well past the protein line, and the one published human report of the injected protein is a retrospective case series of eye findings in bodybuilding athletes [9]. ACE-031 is an antibody fusion protein, a receptor fragment stitched to an antibody tail, tested in a single ascending-dose phase 1 in 48 healthy postmenopausal women [10]. Cerebrolysin is the trade name a hydrolysate of pig brain tissue is sold under. That hydrolysate is a mixture of small peptides and free amino acids rather than a defined molecule of any kind, and the Cochrane review of it in acute ischaemic stroke treats it as a preparation rather than as a compound [11].
What the published record covers for each
The human record that gets quoted for NAD+ was mostly produced by giving people something else. Two randomised, placebo-controlled trials illustrate the shape of it: a 2021 study in Science randomised 25 postmenopausal women with prediabetes and overweight or obesity to oral nicotinamide mononucleotide or placebo for 10 weeks, reporting an increase in insulin-stimulated glucose disposal measured by hyperinsulinaemic clamp [Human RCT] [2], and a 2023 multicentre trial randomised healthy middle-aged adults across several oral amounts against placebo [Human RCT] [3]. Both gave a precursor by mouth. Neither gave NAD+ into a vein.
What sits behind the injected form is a different and much shorter story. A 2026 PRISMA-guided systematic review in Ageing Research Reviews set out to collect outcomes trials of intravenous or intramuscular NAD+ for anti-ageing and wellness indications, and reported that none met its inclusion criteria; what circulates about the infused form in those settings is clinic and user report rather than trial data [Anecdote] [1].
Opening the registry records rather than counting them shows the same split. Of the 44 studies a free-text search on NAD+ and intravenous returned on 2 August 2026, five name an NAD+ or precursor intervention: a recruiting comparison of an injectable nicotinamide riboside product against NAD+ in 70 people, two Chinese hospital studies of an injectable listed as Coenzyme I in haematopoietic recovery and in vascular ageing, a 20 person single-arm study in immune thrombocytopenia, and a completed tracer study that infused a labelled precursor to measure how muscle makes NAD+. None has posted results [6].
The other 39 are trials of tocilizumab, carfilzomib, minocycline, avelumab and a long list of unrelated drugs, returned because the string matched the word intravenous somewhere in the record. A number nobody opened is a number rather than a finding, and this is the clearest example of it in the catalog.
Our takeA coenzyme filed under peptides is a chemistry error with a practical consequence: the trial record that gets quoted for it was produced by giving people an oral precursor, and the systematic review that went looking specifically for trials of the infused form is the most informative document written about it in years.
Frequently asked questions
Is NAD+ a peptide?
No. NAD+ is nicotinamide adenine dinucleotide, a coenzyme made of two nucleotides joined at their phosphate groups. A peptide is a chain of amino acids linked by peptide bonds. NAD+ contains no amino acids and no peptide bond, so the category does not reach it at any chain length.
How long does a chain of amino acids have to be before it stops being a peptide?
FDA's final rule of 21 February 2020, published at 85 FR 10057, defines a protein as any alpha amino acid polymer with a specific, defined sequence greater than 40 amino acids in size [4]. A synthetic chain at or below that length is handled as a drug; above it, the substance is generally regulated as a biological product. That 40 residue line is the boundary the word peptide is doing work around, and it is why the length of a molecule is stated on every page of this site.
Are NMN and nicotinamide riboside the same thing as NAD+?
They are precursors, which means the body converts them toward NAD+ rather than them being NAD+. Both are sold orally as dietary supplements and both carry far more registered human studies than the injected form: on 2 August 2026 the registry returned 49 studies for nicotinamide mononucleotide and 124 for nicotinamide riboside [6]. A trial of a precursor taken by mouth is evidence about that precursor by that route, and this site keeps the two records apart.
What is the regulatory position of injected NAD+?
A query of FDA's approved-products data on 2 August 2026 returned no approved application for nicotinamide adenine dinucleotide, nor for either oral precursor [5]. Separately, the 2026 WADA Prohibited List restricts intravenous infusions to 100 mL per 12 hour period under section M2.2, which makes a large-volume drip a prohibited method for a tested athlete regardless of its contents [7].
What else on a peptide menu is not a peptide?
Several things. 5-Amino-1MQ is a small ring molecule. MK-677 is an orally active small molecule with a completed two year randomised trial behind it [8]. Follistatin-344 is a 344 amino acid glycoprotein, past FDA's protein line [9]. ACE-031 is an antibody fusion protein [10]. Cerebrolysin is the trade name of a hydrolysate of pig brain tissue. That preparation is a mixture of small peptides and free amino acids rather than a defined molecule at all, and the Cochrane review treats it as a preparation [11]. Each is covered on its own group page.
References
- Gallagher C, Emmanuel OO. NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Res Rev. 2026. PMID 41655607 DOI 10.1016/j.arr.2026.103057
- Yoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, Sindelar M, Pietka T, Patterson BW, Imai SI, Klein S. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021. PMID 33888596 DOI 10.1126/science.abe9985
- Yi L, Maier AB, Tao R, Lin Z, Vaidya A, Pendse S, Thasma S, Andhalkar N, Avhad G, Kumbhar V. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience. 2023. PMID 36482258 DOI 10.1007/s11357-022-00705-1
- US Food and Drug Administration. Definition of the Term "Biological Product", final rule. Amends the definition so that protein means any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size. Published 21 February 2020, document 2020-03505. Federal Register, volume 85, page 10057. 2020. Final rule
- US Food and Drug Administration. Drugs@FDA approved products data, queried through the openFDA drug/drugsfda endpoint on 2 August 2026 for nicotinamide adenine dinucleotide, nicotinamide mononucleotide and nicotinamide riboside as active ingredients. No approved application was returned for any of the three. openFDA. 2026. Query endpoint
- US National Library of Medicine, ClinicalTrials.gov. Registry counts run through API v2 on 2 August 2026: nicotinamide mononucleotide 49 studies, nicotinamide riboside 124, and a free-text search on NAD+ and intravenous 44. All 44 of the last set were opened; five name an NAD+ or precursor intervention (NCT06919328, NCT06558253, NCT07328100, NCT06776510 and NCT04905446) and none has posted results. ClinicalTrials.gov. 2026. Registry search
- World Anti-Doping Agency. The 2026 Prohibited List, international standard, effective 1 January 2026. WADA. 2026. Prohibited List
- Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE Jr, Clasey JL, Heymsfield SB, Bach MA, Vance ML, Thorner MO. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008. PMID 18981485 DOI 10.7326/0003-4819-149-9-200811040-00003
- Dağ U, Çağlayan M, Öncül H, Alakuş MF. Central serous chorioretinopathy associated with high-dose follistatin-344: a retrospective case series. Int Ophthalmol. 2020. PMID 32671599 DOI 10.1007/s10792-020-01501-6
- Attie KM, Borgstein NG, Yang Y, Condon CH, Wilson DM, Pearsall AE, Kumar R, Willins DA, Seehra JS, Sherman ML. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2013. PMID 23169607 DOI 10.1002/mus.23539
- Ziganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2023. PMID 37818733 DOI 10.1002/14651858.CD007026.pub7